Asian Journal of Medical Sciences,
Journal Year:
2024,
Volume and Issue:
15(7), P. 137 - 141
Published: July 1, 2024
Background:
Diabetic
dyslipidemia
poses
a
significant
risk
factor
for
cardiovascular
complications
in
patients
with
diabetes
mellitus.
Empagliflozin
and
liraglutide
are
two
commonly
used
medications
management,
yet
their
comparative
efficacy
safety
treating
diabetic
remain
under-explored.
Aims
Objectives:
This
study
aimed
to
assess
the
effectiveness
of
versus
managing
dyslipidemia.
Materials
Methods:
The
enrolled
100
participants
dyslipidemia,
divided
equally
into
empagliflozin
treatment
groups.
Baseline
characteristics,
including
age,
gender
distribution,
ethnicity,
duration
diabetes,
were
assessed
compared
between
Lipid
profiles,
encompassing
total
cholesterol,
low-density
lipoprotein
(LDL)
high-density
(HDL)
triglycerides,
evaluated
at
baseline
after
6
months
treatment.
Safety
outcomes,
such
as
occurrence
mild
gastrointestinal
symptoms,
hypoglycemia,
serious
adverse
events,
also
monitored.
Results:
Both
groups
exhibited
comparable
characteristics.
Following
treatment,
both
demonstrated
improvements
lipid
profiles.
Reductions
LDL
along
increases
HDL
observed
Moreover,
there
no
differences
events
groups,
indicating
similar
Conclusion:
provides
evidence
supporting
These
findings
highlight
potential
viable
therapeutic
options
Nature Medicine,
Journal Year:
2024,
Volume and Issue:
30(10), P. 2849 - 2856
Published: June 24, 2024
Abstract
People
with
type
2
diabetes
and
chronic
kidney
disease
have
a
high
risk
for
failure
cardiovascular
(CV)
complications.
Glucagon-like
peptide-1
receptor
agonists
sodium-glucose
cotransporter-2
inhibitors
(SGLT2i)
independently
reduce
CV
events.
The
effect
of
combining
both
is
unclear.
FLOW
trial
participants
were
stratified
by
baseline
SGLT2i
use
(
N
=
550)
or
no
2,983)
randomized
to
semaglutide/placebo.
primary
outcome
was
composite
failure,
≥50%
estimated
glomerular
filtration
rate
reduction,
death
death.
the
24%
lower
in
all
treated
semaglutide
versus
placebo
(95%
confidence
interval:
34%,
12%).
occurred
41/277
(semaglutide)
38/273
(placebo)
on
at
(hazard
ratio
1.07;
95%
0.69,
1.67;
P
0.755)
290/1,490
372/1,493
not
taking
0.73;
0.63,
0.85;
<
0.001;
interaction
0.109).
Three
confirmatory
secondary
outcomes
predefined.
Treatment
differences
favoring
total
slope
(ml
min
−1
/1.73
m
/year)
0.75
(−0.01,
1.5)
subgroup
1.25
(0.91,
1.58)
non-SGLT2i
subgroup,
0.237.
Semaglutide
benefits
major
events
all-cause
similar
regardless
0.741
0.901,
respectively).
reducing
consistent
with/without
use;
power
limited
detect
smaller
but
clinically
relevant
effects.
ClinicalTrials.gov
identifier:
NCT03819153
.
Cardiovascular Diabetology,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: June 1, 2024
regarding
the
CV
effects
of
oral
semaglutide
in
individuals
with
type
2
diabetes
and
established
ASCVD
and/or
CKD
[46]"
instead
"The
SOUL
study
demonstrated
non-inferiority
to
placebo
terms
mortality
outcomes
[46]".The
updated
Acknowledgements
statement
should
read,
"We
would
like
thank
BioQuest
Solutions
Pvt.Ltd
for
providing
medical
Asian Journal of Medical Sciences,
Journal Year:
2024,
Volume and Issue:
15(7), P. 137 - 141
Published: July 1, 2024
Background:
Diabetic
dyslipidemia
poses
a
significant
risk
factor
for
cardiovascular
complications
in
patients
with
diabetes
mellitus.
Empagliflozin
and
liraglutide
are
two
commonly
used
medications
management,
yet
their
comparative
efficacy
safety
treating
diabetic
remain
under-explored.
Aims
Objectives:
This
study
aimed
to
assess
the
effectiveness
of
versus
managing
dyslipidemia.
Materials
Methods:
The
enrolled
100
participants
dyslipidemia,
divided
equally
into
empagliflozin
treatment
groups.
Baseline
characteristics,
including
age,
gender
distribution,
ethnicity,
duration
diabetes,
were
assessed
compared
between
Lipid
profiles,
encompassing
total
cholesterol,
low-density
lipoprotein
(LDL)
high-density
(HDL)
triglycerides,
evaluated
at
baseline
after
6
months
treatment.
Safety
outcomes,
such
as
occurrence
mild
gastrointestinal
symptoms,
hypoglycemia,
serious
adverse
events,
also
monitored.
Results:
Both
groups
exhibited
comparable
characteristics.
Following
treatment,
both
demonstrated
improvements
lipid
profiles.
Reductions
LDL
along
increases
HDL
observed
Moreover,
there
no
differences
events
groups,
indicating
similar
Conclusion:
provides
evidence
supporting
These
findings
highlight
potential
viable
therapeutic
options
Biomolecules,
Journal Year:
2024,
Volume and Issue:
15(1), P. 39 - 39
Published: Dec. 31, 2024
Sodium-glucose
co-transporter
2
inhibitors
(SGLT2i),
glucagon-like
peptide-1
receptor
agonists
(GLP1a),
and
non-steroidal
mineralocorticoid
antagonists
(ns-MRA)
are
promising
treatments
for
chronic
kidney
disease.
This
umbrella
review
of
network
meta-analyses
evaluated
their
effects
on
cardiovascular
outcomes,
disease
progression,
adverse
events,
using
the
TOPSIS
method
to
identify
optimal
intervention
based
P-scores.
A
total
19
44
randomized
controlled
trials
involving
86,150
patients
were
included.
Compared
placebo,
SGLT2i
associated
with
reduced
risks
events
[Hazard
ratio
(HR):
0.776,
95%
confidence
intervals
(CI):
0.727–0.998],
progression
(HR:
0.679,
CI:
0.629–0.733),
acute
injury
0.873,
0.773–0.907),
serious
0.881,
0.847–0.916).
GLP1a
ns-MRA
also
significant
reductions
in
kidney-specific
composite
outcomes.
Indirect
evidence
showed
that
demonstrated
a
lower
risk
compared
0.826,
0.716–0.952)
0.818,
0.673–0.995),
representing
best
across
all
endpoints.
In
conclusion,
while
SGLT2i,
GLP1a,
reduce
disease,
appears
provide
most
favorable
balance
efficacy
safety.
